Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Eisai, Verastem develop Wnt inhibitors against cancer

Executive Summary

Eisai Co. Ltd. will partner with start-up Verastem Inc. (cancer therapeutics) in a collaboration to generate small-molecule Wnt inhibitors that target cancer stem cells (CSCs), a primary cause of tumor recurrence and metastasis.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Reverse Licensing
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register